For too long, that idea shaped ambitions and professional paths. Today, when Alzheimer’s research requires more talent and greater diversity than ever, it remains a question worth asking.
At Ace Alzheimer Center Barcelona, the answer is not theoretical. It is visible in our laboratories, in our clinics, and in the spaces where scientific decisions are made. Women’s leadership is not an exception within our institution, it is a structural component of our clinical and research model.
Although more than 60% of those choosing neurology as a specialty during their training are women, this majority does not always translate into leadership positions. This gap is particularly relevant considering that Alzheimer’s prevalence is higher in women and that more than 50% will develop a neurodegenerative disease during their lifetime. Promoting scientific vocations among girls and consolidating female leadership in neuroscience is not only a matter of equity, but also of scientific quality.
Established Leadership at Ace
Women represent 81% of Ace’s team, with a presence that spans all levels of the organization. This is not merely representation, it is real leadership. Sixty-seven percent of areas are led by women or include women in key leadership positions, actively contributing to strategic and scientific decision-making within the center.
The General Director of Ace is Miren Jone Gurrutxaga, while the Medical Director is neurologist and co-founder Dr. Mercè Boada. In the clinical and scientific field, key leaders include Dr. Pilar Sanz, neurologist and Head of Clinical Services; Dr. Montse Alegret, Head of Neuropsychology; Dr. Victoria Fernández, Director of the Genetics Program; Dr. Marta Marquié, Head of Clinical Research; and Dr. Amanda Cano, Director of the Molecular Biology and Biomarkers Program.
Their work translates into national and international competitive projects, scientific publications, clinical trials, and the development of innovative diagnostic tools — always with a focus on improving the lives of patients and their families.
More Role Models, Better Research
Research in neurodegenerative diseases demands rigor, creativity, and the ability to integrate diverse perspectives. Increasing the presence of women at every level of the scientific process not only expands the available talent pool, but also enhances the quality of outcomes and strengthens our ability to address complex challenges.
As Dr. Amanda Cano, Director of the Molecular Biology and Biomarkers Program at Ace, states:
“Supporting girls so they can approach and remain in science is not only an act of justice; it is an investment in health.”
On this February 11, we reaffirm our commitment to a science that is diverse, rigorous, and person-centered. The challenge of Alzheimer’s requires the very best talent available. At Ace, we work to ensure that talent, wherever it comes from, finds the space, opportunity, and responsibility needed to transform knowledge into better health.
